Treatment of platelet derived growth factor related disorders such as cancers
AssigneesSugen, Inc., Biosignal Limited, Yissum Research Development Company of the Hebrew University of Jerusalem, Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V.
InventorsKlaus Peter Hirth, Donna Pruess Schwartz, Elaina Mann, Laura Kay Shawver, Gyorgy Keri, Istvan Szekely, Tamas Bajor, Janis Haimichael, Laszlo Orfi, Alex Levitzki, Aviv Gazit, Axel Ullrich, Reiner Lammers
Life of this patent
Estimating the term…
Abstract
Method for treating a patient inflicted with a cell proliferation disorder, such as a cancer, characterized by inappropriate PDGF-R activity. The method involves the step of administering to the patient a therapeutically effective amount of a composition described in application.
Claims23
A method of treating a patient suffering from a carcinoma cancer characterized by inappropriate PDGF-R activity, comprising the step of administering to said patient a therapeutically effective amount of a composition comprising a compound selected from the group consisting of:
- ##STR1## and pharmaceutically acceptable salts thereof.
A method of treating a patient having ovarian cancer characterized by inappropriate PDGF-R activity comprising the step of administering to said patient a therapeutically effective amount of a compound selected from the group consisting of;
- 5-methylisoxazole-4 carboxylic acid-(4-trifluromethyl)-anilide, N-(4-trifluoromethylphenyl)-2-cyano-3-hydroxycrotoamide, and pharmaceutically acceptable salts thereof.
A method of treating a patient having an intra-axial brain cancer characterized by inappropriate PDGF-R activity comprising the step of administering to said patient a therapeutically effective amount of a compound selected from the group consisting of:
- 5-methylisoxazole-4 carboxylic acid-(4-trifluromethyl)-anilide,
- N-(4-trifluoromethylphenyl)-2-cyano-3-hydroxycrotoamide, pharmaceutically acceptable salts thereof.
A method of treating a patient having glioma characterized by inappropriate PDGF-R activity comprising the step of administering to said patient a therapeutically effective amount of a compound selected from the group consisting of:
- 5-methylisoxazole-4 carboxylic acid-(4-trifluromethyl)-anilide,
- N-(4-trifluoromethylphenyl)-2-cyano-3-hydroxycrotoamide, and pharmaceutically acceptable salts thereof.
A method of treating a patient having colon cancer characterized by inappropriate PDGF-R activity comprising the step of administering to said patient a therapeutically effective amount of a compound selected from the group consisting of:
- 5-methylisoxazole-4 carboxylic acid-(4-trifluromethyl)-anilide,
- N-(4-trifluoromethylphenyl)-2-cyano-3-hydroxycrotoamide, and pharmaceutically acceptable salts thereof.
A method of treating a patient having lung cancer characterized by inappropriate PDGF-R activity comprising the step of administering to said patient a therapeutically effective amount of a compound selected from the group consisting of:
- 5-methylisoxazole-4 carboxylic acid-(4-trifluromethyl)-anilide,
- N-(4-trifluoromethylphenyl)-2-cyano-3-hydroxycrotoamide, and pharmaceutically acceptable salts thereof.
A method of treating a patient having prostate cancer characterized by inappropriate PDGF-R activity comprising the step of administering to said patient a therapeutically effective amount of a compound selected from the group consisting of:
- 5-methylisoxazole-4 carboxylic acid-(4-trifluromethyl)-anilide,
- N-(4-trifluoromethylphenyl)-2-cyano-3-hydroxycrotoamide, and pharmaceutically acceptable salts thereof.
A method of treating a patient suffering from either a carcinoma characterized by inappropriate PDGF-R activity or an intra-axial brain cancer characterized by inappropriate PDGF-R activity, comprising the step of administering to said patient a therapeutically effective amount of a compound which forms, in vivo, ##STR4## after administration to said patient.
A method of treating a patient having a cancer selected from the group consisting of:
- a carcinoma and an intra-axial brain cancer, wherein said cancer is characterized by inappropriate PDGF-R activity, comprising the step of administering to said patient a sufficient amount of a compound to reduce PDGF-R activity, said compound selected from the group consisting of 5-methylisoxazole-4 carboxylic acid-(4-trifluromethyl)-anilide,
- N-(4-trifluoromethylphenyl)-2-cyano-3-hydroxycrotoamide, and pharmaceutically acceptable salts thereof.
Dependencies are inferred from the claim text.